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LABORATORY AND CLINICAL STUDIES OF A NEW ANTIBIOTIC,
CEPHALOGLYCIN IN THE TREATMENT OF URINARY TRACT INFECTIONSt
Cephaloglycin, the dipolar ion of 7- (D-a-aminophenylacetamido) cephalo-
sporanic acid, is a phenyl-glycine analogue of the antibiotic cephalothin.
Preliminary studies in vitro, indicate that the drug has bactericidal activity
against Gram-negative as well as Gram-positive bacteria.' The broad spec-
trum of antibacterial activity observed with cephaloglycin is similar to two
earlier derivatives of cephalosporanic acid, cephalothin and cephaloridine,"'
which must be administered parenterally. In contrast, cephaloglycin is
thought to be well absorbed from the gastrointestinal tract because it is
excreted in high concentration in the urine after oral administration in
man,3 which suggests that the drug may be useful in the treatment of cer-
tain bacterial infections, particularly those involving the urinary tract.
The present report describes the absorption, urinary excretion, clinical
effect and toxicity of oral cephaloglycin in patients with urinary tract in-
fections. In addition, sensitivity of 151 Gram-negative organisms to cephalo-
glycin was studied in vitro by comparing the single high-concentration disc
method with the tube-dilution method.
MATERIALS AND METHODS
Clinical studies
Twenty-four patients (22 males and two females from 25 to 79 years of age) with
significant bacteriuria, and who consented to the study, received oral cephaloglycin
treatment. Seven patients were treated for first episode urinary tract infection, where-
as a history of chronic urinary tract infection was obtained from 17. However, 18
of the 24 patients had acute symptoms referable to infection of the urinary tract and
six patients had asymptomatic bacteriuria. Urines were obtained by the clean catch
technique and cultured as previously described.' Significant bacteriuria was defined as
100,000 colonies or more per milliliter of urine per species of bacteria. Urinary tract
infection was arbitrarily defined in each patient as the presence of significant bacteri-
uria in at least two consecutive urine cultures. Intravenous pyelograms and residual
volumes of bladder urine were obtained for each patient to evaluate the presence of
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urinary tract obstruction. The volume of residual bladder urine was determined without
catheterization by a modification of the radioisotope method of Mulrow, et al. using
Ortho-Iodohippuric acid.5 No patient had an indwelling catheter or received other
antibiotic treatment during the period of study.
Cephaloglycin was supplied in 250 mg. capsules* and was administered orally in
doses of 500 mg. every six hours for ten days. In four patients, the dose was decreased
to 250 mg. during the latter five days of treatment. Serum and urine concentrations of
cephaloglycin were determined in 15 patients twenty-four hours after treatment had
been initiated. Blood was drawn from fasting patients two hours after the 6 a.m. dose
of cephaloglycin. Urine was collected for six hours after discarding the 6 a.m. speci-
men, and the volume was measured. Aliquots of urine and serum were frozen and
subsequently analyzed for cephaloglycin activity by Lilly Research Laboratories.
Toxic effects of the drug were assessed by white blood cell count, differential cell
count, hematocrit, platelet count, total and direct bilirubin, serum glutamic oxaloacetic
acid transaminase, alkaline phosphatase, blood urea nitrogen, and urinalysis values
obtained prior to, during, and after therapy. Each patient was questioned and examined
daily for evidence of nausea, vomiting, diarrhea, pruritis, and skin rash.
The effect of treatment was evaluated by means of quantitative clean catch urine
cultures obtained during treatment, and at 4 days, 2, 4, and 6 weeks after treatment
was discontinued.
Clinical response to cephaloglycin was arbitrarily divided into three categories.
Cures were defined as the eradication of bacteriuria during and for at least four weeks
after cephaloglycin treatment. Relapses were defined as the recurrence of bacteriuria
(eradicated during treatment) within four weeks after cephaloglycin was discontinued.
Treatment failures were defined as the persistence of bacteriuria during cephaloglycin
therapy.
Laboratory studies
One hundred fifty-one strains of Gram-negative bacteria isolated from patients with
clinical infections, including the organisms isolated from the patients with bacteriuria,
were studied. Organisms were collected from the Clinical Bacteriology Laboratory,
subcultured, and re-identified according to the scheme of Schaub, Foley, Scott, and
Bailey' in our Research Bacteriology Laboratory before antibiotic sensitivity tests
were performed.
All organisms were tested with cephaloglycin by both tube-dilution and antibiotic
disc methods. Each bacterial strain was tested against cephaloglycin discs containing
5, 15, and 30 ,ug. of antibiotic. As previously reported,' a modification of the single-
disc method of Kirby, Yoshihara, Sundstedt, and Warren,7 and Turck, Lindemeyer,
and Petersdorf8 was used in the present study. Tube dilution sensitivities were also
performed as previously described2 except that nutrient broth at pH 6.6 was used to
stabilize the antibiotic thus permitting accurate interpretation of the minimum in-
hibitory and minimum bactericidal concentrations 24 hours after incubation at 370 C.
Nutrient agar at the same pH was also used for the single-disc cephaloglycin sensi-
tivity studies.
* Supplied by Dr. R. S. Griffith of Eli Lilly and Company, Indianapolis, Indiana.
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RESULTS
Clinical studies:
The effectiveness of cephaloglycin in the treatment of significant urinary
tract infection is demonstrated in Table 1. Bacteriuria was eradicated dur-
ing cephaloglycin treatment in all patients with nonobstructive uropathy.
Twelve patients relapsed with the same organism within two to four weeks
after cessation of therapy. Only four patients were considered cured. Eight
additional patients had an abnormal residual volume of bladder urine
(> 20 ml.) detected after the initiation of therapy and were analyzed
TABLE 1. EFFECT OF ORAL CEPHALOGLYCIN ON BACTERIURIA
Patients Urine Cultures
During Post-
Nonobstructive Pretreatment treatment treatment* Remarks
W.L. K. Aerobacter 0 0 cure
N.A.
F.S.
C.T.
E.G.H.
J.G.
A.K.
E.H.
E.Ha
R.G.
S.K.
R.H.
A.G.
J.K.
W.M.
R.C.
Obstructive
L.B.
F.L.
L.H.
J.Ma
S.M.
W.Ma
G.L.
J.M.
K. Aerobacter
E. coli
P. mirabilis
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
Paracolon
Paracolon
P. mirabilis
P. mirabilis
P. mirabilis
K. Aerobacter
K. Aerobacter
P. mirabilis
P. mirabilis
K. Aerobacter
P. mirabilis
P. rettgeri
Serratia
Serratia
Serratia
Pseudomonas
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
+
+
+
+
+
0
0
0
+
+
+
+
+
+
Serratia
K. Aerobacter
+
+
+
cure
cure
cure
relapset
relapset
relapse
relapse
relapset
relapset
relapse
relapse
relapse
relapse
relapse
relapse
relapse
relapse
relapse
relapse
failure
failure
failure**
failure**
failure**
failure**
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* + signifies relapse with same organism unless indicated.
** Original isolates were resistant to cephaloglycin.
t Dose of cephaloglycin reduced to 250 mg. during latter 5 days of treatment.
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separately. There were no cures in this group. Furthermore, elimination of
bacteriuria was achieved in only three patients during treatment and each
relapsed in the follow-up period, two with a strain different from the pre-
treatment isolate. In addition, bacteriuria persisted during treatment in the
remaining five patients with obstructive uropathy. However, only two of
these five patients were infected with organisms that were sensitive to the
antibiotic. Three patients in this latter group were infected with strains of
Pseudomonas and Serratia that were initially resistant to cephaloglycin.
The sensitivity to cephaloglycin of the organisms isolated from the initial
culture were compared with the sensitivity of the same organisms obtained
following treatment (Table 2). Pre- and post-treatment sensitivities did
not differ by more than one tube-dilution for any given strain, indicating
that no significant increase in drug resistance occurred.
Serum levels of cephaloglycin determined in 15 patients, 2 to 252 hours
following an oral dose of 500 mg., ranged from 0.40 to 3.09 j%g/ml. with a
mean value of 1.46 (Fig. 1). In two additional patients, 250 mg. were
given and serum levels were 0.383, and 0.483 ,ug/ml. Two values fell out-
side the above range of values (9.0 ug/ml. after 250 mg. and 15.0 jug/ml.
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FIG. 1. Serum and urine concentrations of cephaloglycin in patients receiving a 500
mg. oral dose.
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TABLE 2. CEPHALOGLYCIN TUBE DILUTION SENSITIVITY OF URINARY PATHOGENS
ISOLATED BEFORE AND AFTER THERAPY
Patient Organismi Initial culture Follow-up culture
MIC* MBC** MIC* MBC**
A.G. P. mirabilis 12.50 50.00 >50.00
E.Ha E. coli 1.56 3.13 3.13 6.25
E.G.H. E. coli 50.00 >50.00 >50.00
R.H. Paracolon 3.13 3.13 3.13
S.K. Paracolon 1.56 6.25 3.13 6.25
W.L. K. Aerobacter 12.50 12.50 6.25 12.50
W.Ma Serratia >50.00 >50.00 >50.00 >50.00
J.Ma P. rettgeri 50.00 25.00
W.M. K. Aerobacter 25.00 50.00 25.00 50.00
* MIC-minimum inhibitory concentration.
** MBC-minimum bactericidal concentration.
after 500 mg. oral doses) and occurred in patients with chronic renal in-
sufficiency and uremia.
Urine concentrations of cephaloglycin determined in 12 patients without
obstructive uropathy ranged from 35.6 to 524 ,ug/ml. with a mean value of
228 ,ug/ml. following oral doses of 500 mg. (Fig. 1), and 11.5 and 28
jug/ml. in two patients after one oral dose of 250 mg. of drug. The concen-
tration of cephaloglycin in the urine of one patient with an abnormal
residual urine volume was 1232 jug/ml.
Gastrointestinal intolerance was the major side effect of the drug ob-
served during the study. Diarrhea developed in four patients during treat-
ment with a dose of two grams per day but was controlled in each instance
by reducing the dose to one gram per day.
Eosinophilia occurred in three patients during treatment. No other
hematologic, renal or liver toxicity was observed. Three patients developed
mild erythematous skin rashes during the course of therapy and two pa-
tients developed balanitis one week after cessation of treatment. In general,
the drug was well tolerated and in no instance was it necessary to discon-
tinue therapy. Three patients gave a history of penicillin sensitivity but
eosinophilia or allergic reactions were not observed.
Laboratory stutdies
Tube-dilution sensitivity of Gramn-negative isolates to cephaloglycin: The
bacteriostatic and bactericidal activity of cephaloglycin tested against 104
bacterial cells of Escherischia coli, and species of Klebsiella-Aerobacter,
Proteus, Paracolon, Pseudomonas and Serratia are summarized in Table
288
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3 and Figure 2. Strains of Pseudomonas and Serratia were uniformly re-
sistant to high concentrations of cephaloglycin. Furthermore, only 26 per
cent of the remaining bacterial strains tested were inhibited by cephalo-
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CEPHALOGLYCIN (ag/ml)
FIG. 2. Susceptibility of Gram-negative bacteria to increasing concentrations of
cephaloglycin.
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glycin in concentrations (1.56 ,ug/ml.) equal to peak levels observed in
serum after a 500 mg. oral dose in man.8 However, 53 per cent of these
strains were inhibited by 3.13 ,g/ml. of drug, indicating that greater in-
hibition rates might be achievable with larger oral doses of cephaloglycin.
This latter concentration of drug was most effective against the majority
of strains of E. coli (62%o), Proteus (75%), and Paracolon (100%o) or-
ganisms. Nevertheless, there was a poor correlation between peak serum
levels of cephaloglycin achievable in man after a 500 mg. oral dose and the
minimum concentration of this antibiotic necessary for inhibiting bacterial
growth in vitro. In contrast, 90 per cent of the bacterial strains studied,
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FIG. 3. Correlation of results of 30,ug. disc and tube-dilution sensitivities of cephalo-
glycin against Gram-negative bacteria.
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except for strains of Pseudomonas and Serratia, were inhibited by 50 ,g/
ml. of cephaloglycin. This concentration of drug was achieved in the urine
of the majority of our patients after an oral dose of 500 mg.
Conmparison of disc and tube dilution sensitivities: The zone diameter of
inhibition of Gram-negative bacteria tested with 30 Ag. of cephaloglycin is
illustrated in Figure 3. Since the antibiotic disc has a diameter of 6 mm.,
which is included in the final reading, a zone size of 6 mm. indicates no in-
hibition of the growth of the organism. The zone of inhibition for each
strain studied is plotted against the minimum concentration (MIC) of
cephaloglycin, as determined by tube-dilution sensitivity, necessary to in-
hibit the growth of that bacterial strain. Excellent correlation was observed
between disc and tube-dilution sensitivities of cephaloglycin against strains
of Serratia, Pseudomonas, and Paracolon organisms. In addition, equally
good correlation was observed with 29 of 32 (90%o) strains of Proteus.
Twenty-four strains of Proteus had disc zone diameters of inhibition of
18 mm. or more and were inhibited by tube-dilution concentrations of 3.13
jig/ml. or less of cephaloglycin. Five Proteus strains had disc zones of
inhibition less than 18 mm. and required concentrations of 6.25 ug/ml. or
more. In contrast, the tube-dilution sensitivities of only 36 of 53 (68%)o)
strains of E. coli correlated well with the disc sensitivities. Seventeen
strains of E. coli had disc zone diameters of inhibition of 18 mm. or more
but required concentrations of cephaloglycin of 6.25 micrograms or greater
per milliliter to inhibit growth. The greatest discrepancies between disc
and tube-dilution sensitivities were observed with strains of Klebsiella-
Aerobacter species. Twenty-four of the 42 strains studied had disc zone
diameters of inhibition of 18 mm. or more but required concentrations of
cephaloglycin of 6.25 micrograms or more per milliliter before bacterial
growth was inhibited.
Additional comparisons between disc and tube-dilution sensitivities were
made utilizing 5 and 15 jug. discs of cephaloglycin. Smaller zones of inhibi-
tion were observed with lower disc concentrations of cephaloglycin. How-
ever, independent correlations between minimum inhibitory tube-dilution
concentrations and zone diameters of inhibition produced by both the 5
and 15 Ag. discs were identical to the results observed with the 30 ,ug. disc
of cephaloglycin.
DISCUSSION
The introduction of an oral cephalosporin, cephaloglycin, which pos-
sessed a broad spectrum of antimicrobial activity was initially reviewed as
a major development in antimicrobial therapy. Preliminary studies by
others indicated that significant gastrointestinal absorption occurred in
292
Volume40,February, 1968cephaloglycin in uinary infection A
man, despite low serum levels, since high concentrations of cephaloglycin
were observed in the urine of patients following an oral dose of 500 mg.'
These observations suggested that cephaloglycin might be an effective agent
in the treatment of bacteriuria.
The results of the present study confirm some of these earlier observa-
tions. The oral administration of cephaloglycin does produce a high con-
centration of drug in the urine, although serum levels, obtained at the time
of maximum absorption,' remain low. Furthermore, the data indicate that
cephaloglycin is effective in eradicating Gram-negative organisms from the
urine of patients with nonobstructive uropathy during treatment. However,
bacteriuria recurred in the majority of these patients shortly after treat-
ment was discontinued.
The high relapse rate observed in the present study was not due to in-
adequate concentrations of antibiotic in the urine nor to the emergence or
acquisition of organisms resistant to the drug. Furthermore the relapses
observed in patients with nonobstructive uropathy occurred with the same
species and presumably the same strain of bacteria initially recovered from
the urine, which suggests that cephaloglycin merely suppressed bacterial
growth without sterilizing the urine.
The importance of high antibacterial serum levels in the treatment of
renal parenchymal infection has not been precisely defined. Although no
attempt was made in the present study to determine the localization of
bacteriuria to either the upper or lower tracts, the high relapse rate might
be related to the low serum levels achieved after oral administration of the
drug. The tube dilution sensitivity data clearly indicate that the concentra-
tion of cephaloglycin necessary to inhibit or kill the infecting organisms
exceeded the peak concentration of drug which could be achieved in the
serum after an oral dose of 500 mg. Higher daily doses of cephaloglycin or
longer treatment periods might result in better cure rates. Gastrointestinal
intolerance, the major side effect observed, must be considered, however,
and was controlled by reducing the initial dose used in the present study.
Additional side effects observed during treatment included eosinophilia in
three patients and skin rashes in three others. Furthermore, two patients
developed balanitis one week after treatment had been discontinued. Never-
theless, none of the reactions observed was severe or life-threatening and
in no instance was it necessary to discontinue treatment.
The administration of large doses of cephalothin to patients with renal
insufficiency has been associated with a Coombls-positive hemolytic anemia.'
Similarly the use of large doses of cephaloridine has resulted in renal in-
sufficiency in some patients.'0 Normal doses of cephaloglycin were adminis-
tered to two patients with chronic renal insufficiency in the present study.
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Although high serum levels of drug were observed in both, neither patient
developed adverse reactions to the drug. In particular, cephaloglycin was
not associated with further renal insufficiency nor did either patient experi-
ence a fall in hematocrit values. Nevertheless, the drug should be used
cautiously in patients with renal impairment. Furthermore, the low serum
levels observed in patients with normal renal fuction suggest that cephalo-
glycin should not be used to treat infections outside the urinary tract.
Finally, the results of the laboratory data observed in the present study
indicate that, with the exception of some strains of Klebsiella-Aerobacter
and a few strains of E. coli, the single high-concentration disc method cor-
relates closely with the tube-dilution method. The strains separated into
two distinct populations, sensitive and resistant, with few intermediate
strains, and exhibited a "bimodal distribution." The single high-concentra-
disc method is reliable in determining the antimicrobial sensitivity or re-
sistance of strains of Serratia, Pseudomonas, Paracolon, and Proteus and
the majority of strains of E. coli to cephaloglycin.
SUMMARY
The oral administration of cephaloglycin, a new semisynthetic antibiotic,
resulted in high concentrations of drug in the urine, although serum levels
remained low. However, high concentrations of cephaloglycin were ob-
served in the serum of two patients with renal insufficiency following oral
administration of the drug. Although cephaloglycin was effective in eradi-
cating Gram-negative organisms from the urine of patients with non-
obstructive uropathy during treatment, bacteriuria recurred in the majority
shortly after treatment was discontinued. Gastrointestinal intolerance oc-
curred in four patients and was the most significant adverse effect observed,
In vuitro sensitivity studies of 151 Gram-negative bacteria indicated that,
with the exception of some strains of Klebsiella-Aerobacter, the single
high-concentration disc method compared favorably with the tube-dilution
method and was reliable in determining the antimicrobial sensitivity of
strains of Serratia, Pseudomonas, Paracolon, Proteus, and the majority of
strains of E. coli to cephaloglycin. Furthermore, cephaloglycin was not ef-
fective against Pseudomonas or Serratia organisms.
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